Play all audios:
Last November and then again in February, Bristol Myers Squibb said its oral drug designed to treat psoriasis differently from currently approved medicines had achieved the goals of large
Phase 3 clinical trials. On Friday, the actual data from those two studies were presented publicly for the first time at the annual meeting of the American Academy of Dermatology. The
Bristol drug, called deucravacitinib, proved more effective at clearing the chronic skin disease — numerically and statistically — compared to a placebo and a competing drug from Amgen. The
safety data from the two clinical trials also suggest deucravacitinib, taken as a once-daily pill, is better tolerated and less toxic than a related class of autoimmune pills called JAK
inhibitors, all of which carry the highest level of FDA-mandated safety warnings for serious infections, blood clots, and cancer. STAT+ Exclusive Story Already have an account? Log in THIS
ARTICLE IS EXCLUSIVE TO STAT+ SUBSCRIBERS UNLOCK THIS ARTICLE — PLUS DAILY COVERAGE AND ANALYSIS OF THE PHARMA INDUSTRY — BY SUBSCRIBING TO STAT+. Already have an account? Log in Individual
plans Group plans View All Plans To read the rest of this story subscribe to STAT+. Subscribe